When was mbiomics founded?

mbiomics was founded in 2020 and raised its 1st funding round 3 years after it was founded.

Where is mbiomics located?

mbiomics is headquartered in Munich, Germany.

How many employees does mbiomics have?

As of Sep 30, 2026, the latest employee count at mbiomics is 44.

Is mbiomics a funded company?

mbiomics is a funded company, having raised a total of $35.2M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Mar 23, 2023.

When was the latest funding round of mbiomics?

mbiomics' latest funding was a $***** Series A round on Apr 28, 2026, with participation from 2 investors.

Where does mbiomics rank among its competitors?

mbiomics ranks 390th amongst 3509 active competitors, of which 1165 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of mbiomics?

mbiomics' top competitors include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Among them, Immuneel secured the most recent funding round in June, 2026.

mbiomics - 2026 Company Profile, Team, Funding, Competitors & Financials

mbiomics is a series A company based in Munich (Germany), founded in 2020 by Heinrich Grabmayr and Johannes B Woehrstein. It operates as a Provider of a genomic-based platform for microbiome-based therapeutics development. mbiomics has raised $35.2M in funding from Bayern Kapital and MIG Fonds. The company has 3509 active competitors, including 1165 funded and 801 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Kite Pharma.

Company Details

Provider of a genomic-based platform for microbiome-based therapeutics development. It offers platforms that combine DNA and RNA analysis for single or molecule detection which includes GOLD for microbiome analysis, monitors to track microbiome modulation, and STRATOS for microbiome profiling.

Website: mbiomics.com
Email ID: *****@mbiomics.com
Phone Number: +49 **********

Key Metrics

Founded Year

2020

Location

Munich, Germany

Stage

Series A

Total Funding

$35.2M in 2 rounds

Latest Funding Round

Series A, Apr 28, 2026, $*****

Investors

Bayern Kapital & 2 more

Ranked

390^th among 3509 active competitors

Employee Count

44 as on Sep 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3126 more

View mbiomics' full profile

mbiomics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
mbiomics GmbH CIN: HRB255962 , Germany, Active	Apr 05, 2020	-	-

mbiomics has raised a total funding of $35.2M over 2 rounds. Its first funding round was on Mar 23, 2023. Its latest funding round was a Series A round on Apr 28, 2026 for $*****. 2 investors participated in its latest round. mbiomics has 3 institutional investors.

Here is the list of recent funding rounds of mbiomics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 28, 2026	8792124	Series A	3603335	7935266	7326148	5681976
Mar 23, 2023	7707395	Series A	5573986	6943235	Bayern Kapital & 1 more	HTGF

Access funding benchmarks and valuations. Sign up today!

View details of mbiomics's funding rounds and investors

The founders of mbiomics are Heinrich Grabmayr and Johannes B Woehrstein.

Here are the details of mbiomics' key team members:

Heinrich Grabmayr: Co-Founder of mbiomics.
Johannes B Woehrstein: Co-Founder of mbiomics.

View details of mbiomics's Founder profiles and Board Members

mbiomics' employee count trend

mbiomics has 44 employees as of Sep 26. Here is mbiomics's employee count trend over the years:

Uncover mbiomics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of mbiomics include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of mbiomics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	76/100
4th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
5th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
7th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
8th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
9th	Attovia 2023, Fremont (United States), Public	Developer of antibody-based therapeutics for immune-mediated diseases and oncology	$255M	Deep Track Capital, Goldman Sachs Asset Management ... & 13 others	71/100
10th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	71/100
390th	mbiomics 2020, Munich (Germany), Series A	Provider of a genomic-based platform for microbiome-based therapeutics development	$35.2M	MIG Fonds, Bayern Kapital & 1 others	57/100